| Ytd | -37.16% | |
| 1y | 5.21% |
| Open | 6.35 | Prev Close | 6.34 | Low | 6.19 | High | 6.55 | Mkt Cap | 250.78M |
| Vol | 511.49K | Avg Vol | 447.85K | EPS | -3.99 | P/E | -1.62 | Forward P/E | -5.54 |
| Beta | -0.26 | Short Ratio | 11.43 | Inst. Own | 80.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 6.84 | 200-d Avg | 9.63 | 1yr Est | 26.43 |
TRDA News
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Ther
LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims o
Entrada Therapeutics NASDAQ: TRDA said initial data from the first cohort of its phase I/II ELEVATE-
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See wh
Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to n
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.95 per share versus the Zacks
500 - Internal server error. Server Error 500 - Internal server error.
During Thursday, 849 stocks hit new 52-week lows.